FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2022389416> ?p ?o ?g. }

• W2022389416 endingPage "1079" @default.
• W2022389416 startingPage "1068" @default.
• W2022389416 abstract "Oncolytic herpes viruses are attenuated, replication-competent viruses that selectively infect, replicate within, and lyse cancer cells and are highly efficacious in the treatment of a wide variety of experimental cancers. The current study seeks to define the pharmacologic interactions between chemotherapeutic drugs and the oncolytic herpes viral strain NV1066 in the treatment of pancreatic cancer cell lines. The human pancreatic cancer cell lines Hs 700T, PANC-1, and MIA PaCa-2 were treated in vitro with NV1066 at multiplicities of infection (MOI; ratio of the number of viral particles per tumor cell) ranging from 0.01 to 1.0 with or without 5-fluorouracil (5-FU) or gemcitabine. Synergistic efficacy was determined by the isobologram and combination-index methods of Chou and Talalay. Viral replication was measured using a standard plaque assay. Six days after combination therapy, 76% of Hs 700T cells were killed compared with 43% with NV1066 infection alone (MOI = 0.1) or 0% with 5-FU alone (2 micromol/L) (P < .01). Isobologram and combination-index analyses confirmed a strongly synergistic pharmacologic interaction between the agents at all viral and drug combinations tested (LD5 to LD95) in the three cell lines. Dose reductions up to 6- and 78-fold may be achieved with combination therapy for NV1066 and 5-FU, respectively, without compromising cell kill. 5-FU increased viral replication up to 19-fold compared with cells treated with virus alone. Similar results were observed by combining gemcitabine and NV1066. We have demonstrated that 5-FU and gemcitabine potentiate oncolytic herpes viral replication and cytotoxicity across a range of clinically achievable doses in the treatment of human pancreatic cancer cell lines. The potential clinical implications of this synergistic interaction include improvements in efficacy, treatment-associated toxicity, tolerability of therapeutic regimens, and quality of life. These data provide the cellular basis for the clinical investigation of combined oncolytic herpes virus therapy and chemotherapy in the treatment of pancreatic cancer." @default.
• W2022389416 created "2016-06-24" @default.
• W2022389416 creator A5002131520 @default.
• W2022389416 creator A5005824918 @default.
• W2022389416 creator A5026225196 @default.
• W2022389416 creator A5034626553 @default.
• W2022389416 creator A5070121219 @default.
• W2022389416 creator A5070616777 @default.
• W2022389416 creator A5075163677 @default.
• W2022389416 creator A5080646644 @default.
• W2022389416 date "2005-11-01" @default.
• W2022389416 modified "2023-10-16" @default.
• W2022389416 title "5-Fluorouracil and Gemcitabine Potentiate the Efficacy of Oncolytic Herpes Viral Gene Therapy in the Treatment of Pancreatic Cancer" @default.
• W2022389416 cites W1491759514 @default.
• W2022389416 cites W1567268169 @default.
• W2022389416 cites W1913292571 @default.
• W2022389416 cites W1933198004 @default.
• W2022389416 cites W1967321715 @default.
• W2022389416 cites W1970212185 @default.
• W2022389416 cites W1974219858 @default.
• W2022389416 cites W1979889375 @default.
• W2022389416 cites W1981785871 @default.
• W2022389416 cites W1992610170 @default.
• W2022389416 cites W2002845859 @default.
• W2022389416 cites W2010397777 @default.
• W2022389416 cites W2015083350 @default.
• W2022389416 cites W2016416714 @default.
• W2022389416 cites W2022472349 @default.
• W2022389416 cites W2035270983 @default.
• W2022389416 cites W2045564246 @default.
• W2022389416 cites W2060932390 @default.
• W2022389416 cites W2068256457 @default.
• W2022389416 cites W2071655635 @default.
• W2022389416 cites W2077945404 @default.
• W2022389416 cites W2091123311 @default.
• W2022389416 cites W2103594464 @default.
• W2022389416 cites W2105879003 @default.
• W2022389416 cites W2108502900 @default.
• W2022389416 cites W2112259520 @default.
• W2022389416 cites W2170001605 @default.
• W2022389416 cites W2177087014 @default.
• W2022389416 cites W2409887637 @default.
• W2022389416 cites W4250448824 @default.
• W2022389416 doi "https://doi.org/10.1016/j.gassur.2005.06.024" @default.
• W2022389416 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/1373688" @default.
• W2022389416 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16269377" @default.
• W2022389416 hasPublicationYear "2005" @default.
• W2022389416 type Work @default.
• W2022389416 sameAs 2022389416 @default.
• W2022389416 citedByCount "53" @default.
• W2022389416 countsByYear W20223894162012 @default.
• W2022389416 countsByYear W20223894162013 @default.
• W2022389416 countsByYear W20223894162014 @default.
• W2022389416 countsByYear W20223894162015 @default.
• W2022389416 countsByYear W20223894162017 @default.
• W2022389416 countsByYear W20223894162018 @default.
• W2022389416 countsByYear W20223894162019 @default.
• W2022389416 countsByYear W20223894162021 @default.
• W2022389416 countsByYear W20223894162023 @default.
• W2022389416 crossrefType "journal-article" @default.
• W2022389416 hasAuthorship W2022389416A5002131520 @default.
• W2022389416 hasAuthorship W2022389416A5005824918 @default.
• W2022389416 hasAuthorship W2022389416A5026225196 @default.
• W2022389416 hasAuthorship W2022389416A5034626553 @default.
• W2022389416 hasAuthorship W2022389416A5070121219 @default.
• W2022389416 hasAuthorship W2022389416A5070616777 @default.
• W2022389416 hasAuthorship W2022389416A5075163677 @default.
• W2022389416 hasAuthorship W2022389416A5080646644 @default.
• W2022389416 hasBestOaLocation W20223894162 @default.
• W2022389416 hasConcept C121608353 @default.
• W2022389416 hasConcept C126322002 @default.
• W2022389416 hasConcept C140704245 @default.
• W2022389416 hasConcept C159047783 @default.
• W2022389416 hasConcept C2522874641 @default.
• W2022389416 hasConcept C2776999253 @default.
• W2022389416 hasConcept C2780210213 @default.
• W2022389416 hasConcept C2780258809 @default.
• W2022389416 hasConcept C502942594 @default.
• W2022389416 hasConcept C54355233 @default.
• W2022389416 hasConcept C71924100 @default.
• W2022389416 hasConcept C81885089 @default.
• W2022389416 hasConcept C82210918 @default.
• W2022389416 hasConcept C86803240 @default.
• W2022389416 hasConcept C98274493 @default.
• W2022389416 hasConceptScore W2022389416C121608353 @default.
• W2022389416 hasConceptScore W2022389416C126322002 @default.
• W2022389416 hasConceptScore W2022389416C140704245 @default.
• W2022389416 hasConceptScore W2022389416C159047783 @default.
• W2022389416 hasConceptScore W2022389416C2522874641 @default.
• W2022389416 hasConceptScore W2022389416C2776999253 @default.
• W2022389416 hasConceptScore W2022389416C2780210213 @default.
• W2022389416 hasConceptScore W2022389416C2780258809 @default.
• W2022389416 hasConceptScore W2022389416C502942594 @default.
• W2022389416 hasConceptScore W2022389416C54355233 @default.
• W2022389416 hasConceptScore W2022389416C71924100 @default.
• W2022389416 hasConceptScore W2022389416C81885089 @default.
• W2022389416 hasConceptScore W2022389416C82210918 @default.
• W2022389416 hasConceptScore W2022389416C86803240 @default.

• next